A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia (Q54590599)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 11, 2011

Language	Label	Description	Also known as
English	A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia	scientific article published on May 11, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia (English)

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21565405

1 December 2024

7

object named as

Naokuni Uike

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

author name string

Kosuke Tsuboi

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Toshiya Yokozawa

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Toru Sakura

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Takashi Watanabe

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Shin Fujisawa

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Takahiro Yamauchi

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Kiyoshi Ando

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Rika Kihara

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Kensei Tobinai

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Hiroya Asou

11

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Tomomitsu Hotta

12

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Shuichi Miyawaki

13

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21565405

1 December 2024

publication date

11 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

full work available at URL

https://api.elsevier.com/content/article/PII:S0145212611001950?httpAccept=text/xml

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

https://api.elsevier.com/content/article/PII:S0145212611001950?httpAccept=text/plain

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

35

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

1384-1389

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/IJC.25178

Therapeutic Advances in Acute Myeloid Leukemia

1

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Acute myeloid leukemia and myelodysplastic syndromes in older patients

2

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Acute myeloid leukemia

3

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

The outcomes and costs of acute myeloid leukemia among the elderly

5

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Aurora kinases link chromosome segregation and cell division to cancer susceptibility

7

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase

8

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.

9

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.

11

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

12

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

13

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Analysis of Aurora B kinase in non-Hodgkin lymphoma

16

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

17

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

18

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

20

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

22

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

23

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

31

1 reference

10.1016/J.LEUKRES.2011.04.008

https://api.crossref.org/works/10.1016/J.LEUKRES.2011.04.008

1 December 2024

Identifiers

10.1016/J.LEUKRES.2011.04.008

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

release_vlpu7ic24fanxafpty6gj5jbyi

1 reference

https://api.fatcat.wiki/v0/release/vlpu7ic24fanxafpty6gj5jbyi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21565405

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54590599&oldid=2282454494"